scholarly journals Clinical outcomes of people with Fabry Disease - ANZDATA Registry Study

2021 ◽  
Author(s):  
Monica S. Ng ◽  
Eva Malacova ◽  
Cameron Hurst ◽  
David W. Johnson ◽  
Andrew J. Mallett
Keyword(s):  
Fabry Disease ◽  
Clinical Outcomes ◽  
Registry Study ◽  
Anzdata Registry

scholarly journals RADT-47. A MULTICENTER OBSERVATIONAL STUDY OF SURGICALLY TARGETED RADIATION THERAPY (START) USING IMPLANTED CS-131 SEEDS IN A COLLAGEN-BASED CARRIER TILE IN INTRACRANIAL BRAIN NEOPLASMS - PROTOCOL IN PROGRESS

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii191-ii192
Author(s):  
Peter Nakaji ◽  
David Brachman ◽  
Lisa Misell
Keyword(s):  
Radiation Therapy ◽  
Brain Tumors ◽  
Clinical Outcomes ◽  
Local Control ◽  
Real World ◽  
Functional Decline ◽  
Registry Study ◽  
Multicenter Observational Study ◽  
Patient Reported ◽  
Targeted Radiation Therapy

Abstract INTRODUCTION Post-resection radiotherapy (RT) is the most effective adjuvant treatment for brain tumors. However, there is no current consensus as to the “best” type of post-resection RT, either at diagnosis or recurrence. The use of internally placed radiation (brachytherapy) allows immediate initiation of RT when residual tumor burden is minimal, which theoretically should lessen the risk of recurrence. Brachytherapy placement intraoperatively allows more precise identification of the tumor margins than by postoperative imaging. Traditional brachytherapy methods have several drawbacks, including uneven dose distribution, long operating room times, a need for expensive equipment, and/or frequent adverse events (AE). To address these issues, a device with Cs-131 radiation seeds in a resorbable collagen-based carrier tile (GammaTile, GT Medical Technologies, Tempe AZ) was developed and is described as Surgically Targeted Radiation Therapy or STaRT. The device has demonstrated excellent safety and local control in early commercial use. OBJECTIVE The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT. METHOD Patients (N=600) with surgically resected (R) brain tumors of any pathology who have undergone STaRT are eligible. Accrual to start at 20+ sites in Q3 2020. Data collected includes local control, overall survival, QOL, neurocognition, functional decline, and surgical and radiation associated AE’s. Data will be collected at 1, 3, 6, 9, and 12 months, then every 6 months through 5 years. RESULT Data will be used to benchmark clinical outcomes of STaRT therapy and allow for comparisons to existing standard-of-care treatments. CONCLUSION This will be the first observational registry study of R+STaRT, delivered by Cs-131 sources in permanently implanted resorbable collagen tile carriers. The outcome measures captured will allow for evaluation of the potential risks and benefits of this treatment approach for patients in a real-world setting.

Canadian Fabry disease registry study group: Report on the A143P Nova Scotia genotype

2021 ◽  
Vol 132 (2) ◽  
pp. S111
Author(s):  
Michael L. West ◽  
Daniel G. Bichet ◽  
Mark R. Iwanochko ◽  
Sandra Sirrs ◽  
Aneal Khan ◽  
...  
Keyword(s):  
Nova Scotia ◽  
Fabry Disease ◽  
Study Group ◽  
Registry Study ◽  
Disease Registry ◽  
Group Report

Long-term clinical outcomes of patients treated with elosulfase alfa: Five-year real-world results from the Morquio A Registry Study (MARS)

2020 ◽  
Vol 129 (2) ◽  
pp. S112
Author(s):  
John Mitchell ◽  
Uma Ramaswami ◽  
Nicola Longo ◽  
Yin-Hsiu Chien ◽  
Nathalie Guffon ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Real World ◽  
Registry Study ◽  
Morquio A ◽  
Elosulfase Alfa

Clinical Outcomes in Renal Transplant Recipients With Fabry Disease.

2014 ◽  
Vol 98 ◽  
pp. 505
Author(s):  
T. Sandes- Freitas ◽  
G. Mata ◽  
C. Pinto ◽  
L. Custodio ◽  
G. Kirsztajn ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Fabry Disease ◽  
Clinical Outcomes ◽  
Renal Transplant Recipients ◽  
Transplant Recipients

scholarly journals Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study

2017 ◽  
Vol 249 ◽  
pp. 119-126 ◽  
Author(s):  
Jiang Ming Fam ◽  
Cordula Felix ◽  
Yuki Ishibashi ◽  
Yoshinobu Onuma ◽  
Roberto Diletti ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Registry Study ◽  
Vascular Scaffolds ◽  
Bioresorbable Vascular Scaffolds

scholarly journals Clinical Profile, Pharmacological Treatment, and Predictors of Death Among Hospitalized COVID-19 Patients With Acute Kidney Injury: A Population-Based Registry Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Débora Martín-García ◽  
Eduardo Tamayo ◽  
F. Javier Álvarez ◽  
Francisco Herrera-Gómez
Keyword(s):  
Acute Kidney Injury ◽  
Clinical Outcomes ◽  
Kidney Injury ◽  
Population Based ◽  
Hospital Death ◽  
Registry Study ◽  
Acute Dialysis ◽  
Population Based Registry ◽  
Very High ◽  
Registry Analysis

Introduction: One of the worst clinical outcomes of the coronavirus disease 2019 (COVID-19) pandemic was acute kidney injury (AKI).Methods: This manuscript presents results from a population-based registry study assessing treatment, comorbidities, and predictors of hospital death among COVID-19 patients with AKI from March 1st to May 31th, 2020. Death, oxygen delivery and ventilation, acute dialysis need, use of medications, and various clinical outcomes, in addition to the length of stay in the hospital and intensive care unit (ICU), were evaluated.Results: In Castile and Leon, the largest region of Spain, 10.87% of the patients admitted for COVID-19 (n = 7,307) developed AKI. These patients were known by having hypertension (57.93%), cardiovascular disease (48.99%), diabetes (26.7%) and chronic kidney disease (14.36%), and they used antibiotics (90.43%), antimalarials (60.45%), steroids (48.61%), antivirals (33.38%), anti-systemic inflammatory response syndrome (SIRS) drugs (9.45%), and tocilizumab (8.31%). Mortality among patients with AKI doubled that observed in patients without AKI (46.1 vs. 21.79%). Predictors of hospital death in COVID-19 patients with AKI were ventilation needs (OR = 5.9), treatment with steroids (OR = 1.7) or anti-SIRS (OR = 2.4), severe acute respiratory syndrome (SARS) occurrence (OR = 2.8), and SIRS occurrence (OR = 2.5).Conclusions: Acute kidney injury is a frequent and serious complication among COVID-19 patients, with a very high mortality, that requires more attention by treating physicians, when prescribing medications, by looking for manifestations particular to the disease, such as SARS or SIRS.

Sign in / Sign up

Export Citation Format

Share Document